NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that revenues for its fourth quarter increased 16 percent year over year on the strength of its assays and related products as well as consumables sales.

Total revenues for the three months ended Dec. 31, 2012 were $55.5 million, up from $47.9 million in the year-ago period, and beat the consensus Wall Street estimate of $54.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.